Table 3.
Correlation between mRNA Expression of CD247 and CD4 with Relapse Free Survival (RFS) in Pietenpol Subtypes of Triple Negative Breast Cancer.
| Gene | TNBC Subtype |
No. of patients | Hazard Ratio | P value | RFS (in Months) | |
|---|---|---|---|---|---|---|
| Low expression Cohort | High expression Cohort | |||||
| Basal-like(BL1) | 251 | 0.73 | 0.15 | 18.35 | 29 | |
| CD247 | Basal Like (BL2) | 101 | 1.29 | 0.4 | 18 | 19 |
| Immunomodulatory | 300 | 0.9 | 0.6 | 67.09 | 84.23 | |
| Mesenchymal | 211 | 0.71 | 0.09 | 14.64 | 17.45 | |
| Mesenchymal stem-like (MSL) | 81 | 0.86 | 0.68 | 18 | 34.8 | |
| Luminal androgen receptor | 253 | 0.61 | 0.01 | 14.7 | 26.15 | |
| Basal-like (BL1) | 251 | 0.42 | 9.90E-05 | 14.85 | 77.28 | |
| CD4 | Basal Like (BL2) | 101 | 0.83 | 0.54 | 18.18 | 19 |
| Immunomodulatory (IM) | 300 | 0.56 | 0.01 | 35 | 114.96 | |
| Mesenchymal (M) | 211 | 0.54 | 0.0026 | 12.56 | 25 | |
| Mesenchymal stem-like (MSL) | 81 | 1.16 | 0.68 | 25 | 24 | |
| Luminal androgen receptor (LAR) | 253 | 0.56 | 0.0033 | 16 | 27 | |